Age at diagnosis over the last decades – Analysis of the German MS Registry
ECTRIMS Online Library. Haas J. Oct 27, 2017; 200530
Judith Haas
Judith Haas
Login now to access Regular content available to all registered users.

You may also access this content "anytime, anywhere" with the Free MULTILEARNING App for iOS and Android
Discussion Forum (0)
Rate & Comment (0)

Abstract: P875

Type: Poster

Abstract Category: Clinical aspects of MS - 5 Epidemiology

Background: There is an ongoing discussion concerning an increasing number of young female MS patients aged less than 30 years at diagnosis. The increasing risk is supposed to be influenced by changes of lifestyle. Late first pregnancy, obesity, smoking are discussed as risk factors as well. Furthermore the widespread access to MRI facilities may lead to earlier diagnosis.
Methods: Data from the German MS-Registry was extracted in May 2017. Only patients with data available concerning the date of diagnosis, date of birth and sex (N=43465) were analysed. To account for the widespread availability of MRI in 1990ies we started analyses regarding the diagnosis cohorts with the year of diagnosis in 1990. We analysed the percentage of MS patients with an age at diagnosis ≤18 and ≤30 >18 years for the whole population using 5-year intervals. Furthermore we investigated differences in sex and date of birth.
Results: The mean age at diagnosis were 35.63 (±10.88) years. 1313 patients (3.02%) were ≤18 years and 14386 patients (33.1%) were ≤30 years old at the time of diagnosis. In the group with an age at diagnosis ≤18 years 74.71% (N=981) were females and in the group with an age at diagnosis >18 and ≤30 years 72.93% (N=10491) were females. The distribution over diagnosis cohorts revealed in 1990-94: 45.3% [F:73.5%], 1995-99: 33.5% [F:73.1%], 2000-04: 27.5% [F:71.25%], 2005-09: 27.9% [F:72.7 %] and 2010-14: 29.5% [F:71.33%] of the patients were >18 and ≤30 years old at diagnosis. Furthermore we looked into the risk for early onset MS in regard to birth cohorts. The risk of diagnosis at age ≤18 years for patients born 1948-57 was 0.4%, in 1958-67: 0.8%, in 1968-77: 1.8% and in 1978-87: 6.0%. Patients born between 1948-57 had a risk for diagnosis at age >18 and ≤30 years of 8.2%, in 1958-67: 17.6%, 1968-77: 34.7% and in 1978-87: 70.6%.
Conclusions: The analysis of our data did not reveal an increase of young women with an age < = 30 years at diagnosis over the last decades in regard to the diagnosis cohorts. Thus we did see an increasing risk for patients born in recent decades to receive an early MS diagnosis (≤18 and ≤30 years). Further analyses are due to control for possible biases e.g. concerning the type of documented patients in our centers, to and to confirm these early results.
, Kleinschnitz, Rienhoff and Stahmann: declare nothing to disclose.
Flachenecker: has received speaker fees and honoraria from Almirall, Bayer Schering, Biogen Idec, Merck Serono, Novartis and Sanofi; research grants from Bayer Schering, Merck Serono and Sanofi.
Friede: reports personal fees for consultancies (including DMCs) from Novartis, Biogen, AstraZeneca, Bayer, Janssen, SGS, and Pharmalog outside the submitted work.ived compensation from Almirall, Biogen, Bayer, Octapharma, Teva, Allergan, and Novartis.
Haas: received compensation from Almirall, Biogen, Bayer, Octapharma, Teva, Allergan, and Novartis.
: Received institutional research grants and personal honoraria as speaker from Almirall, Biogen Idec, Bayer, Genzyme, Merck Serono, Novartis and TEVA Sanofi
Rommer: Reports travel support from Genzyme, Teva, Roche; has received speaker and consultant honorary from Biogen, Genzyme, Merck, Teva, Roche; has received research support from Merck and Roche
Zettl: Received institutional research grants and personal honoraria as speaker from Biogen Idec, Bayer, Genzyme, Merck Serono, Novartis and TEVA Sanofi
The German MS Society, National Association yearly publishes the received grants and sources of funding: - The consented guidelines by the association of self-help organizations and the DMSG-guidelines for co-operation with (pharmaceutical) companies apply.

Code of conduct/disclaimer available in General Terms & Conditions
Anonymous User Privacy Preferences

Strictly Necessary Cookies (Always Active)

MULTILEARNING platforms and tools hereinafter referred as “MLG SOFTWARE” are provided to you as pure educational platforms/services requiring cookies to operate. In the case of the MLG SOFTWARE, cookies are essential for the Platform to function properly for the provision of education. If these cookies are disabled, a large subset of the functionality provided by the Platform will either be unavailable or cease to work as expected. The MLG SOFTWARE do not capture non-essential activities such as menu items and listings you click on or pages viewed.

Performance Cookies

Performance cookies are used to analyse how visitors use a website in order to provide a better user experience.

Google Analytics is used for user behavior tracking/reporting. Google Analytics works in parallel and independently from MLG’s features. Google Analytics relies on cookies and these cookies can be used by Google to track users across different platforms/services.

Save Settings